Northwest, Lonza Battle Over Gene Patents

Law360, New York (August 1, 2007, 12:00 AM EDT) -- Cancer treatment developer Northwest Biotherapeutics Inc. plans to dispute a patent infringement suit filed last week by rival biotechnology company Lonza Group AG, Northwest said Wednesday.

In a complaint filed July 27 in the U.S. District Court for the District of Delaware, Lonza claimed that Northwest’s cancer vaccine therapies infringe eight patents covering gene expression technology. Lonza alleged that its licensee, Medarex Inc., unlawfully licensed its technology to Northwest, and said that Lonza’s subsequent attempts to reach a licensing agreement with Northwest have failed.

Northwest develops,...
To view the full article, register now.